A Phase II/III, Double-Blind, Placebo-Controlled Study of ME2125 in Patients with Parkinson's Disease with Wearing-Off Phenomenon
Active, no longer recruiting
Phase of Trial: Phase II/III
Latest Information Update: 06 Oct 2017
At a glance
- Drugs Safinamide (Primary) ; Levodopa
- Indications Parkinson's disease
- Focus Therapeutic Use
- Sponsors Meiji Seika Pharma
- 29 Jun 2017 Status changed from recruiting to active, no longer recruiting.
- 09 Oct 2015 New trial record
- 07 Oct 2015 According to a Meiji media release, this trial has been initiated.